FDA OK's United Therapeutics oral PAH drug Orenitram on 3rd try
This article was originally published in Scrip
Executive Summary
The US FDA late on 20 December surprised Wall Street by approving United Therapeutics' new drug application (NDA) to market its oral treprostinil diolamine product under the brand name Orenitram as a treatment for pulmonary arterial hypertension (PAH) in WHO Group I patients to improve exercise capacity.